AR109847A1 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
AR109847A1
AR109847A1 ARP170102922A ARP170102922A AR109847A1 AR 109847 A1 AR109847 A1 AR 109847A1 AR P170102922 A ARP170102922 A AR P170102922A AR P170102922 A ARP170102922 A AR P170102922A AR 109847 A1 AR109847 A1 AR 109847A1
Authority
AR
Argentina
Prior art keywords
polypeptide
seq
amino acid
set forth
sequences described
Prior art date
Application number
ARP170102922A
Other languages
English (en)
Inventor
Ric Brouillette
Julie Ct-Gravel
Cline Ster
Franois Malouin
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of AR109847A1 publication Critical patent/AR109847A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un constructo de fusión de fórmula [1]: X-A-ligante-B-Z [1] donde: (1) A y B son idénticos o diferentes y son independientemente: (a) un polipéptido que comprende un polipéptido SACOL0029 según lo expuesto en cualquiera de las secuencias descritas en Fig. 24 (SEC ID Nº 5 y 121 a 131), un polipéptido SACOL0264 (SEC ID Nº 185), un polipéptido SACOL0442 según lo expuesto en cualquiera de las secuencias descritas en Fig. 22D (SEC ID Nº 29 y 82 a 92), un polipéptido SACOL0718 (SEC ID Nº 186), un polipéptido SACOL0720 según lo expuesto en cualquiera de las secuencias descritas en Figs. 23I-J (SEC ID Nº 11 y 109 a 120), un polipéptido SACOL1353 (SEC ID Nº 187), un polipéptido SACOL1416 (SEC ID Nº 188), un polipéptido SACOL1611 (SEC ID Nº 189), un polipéptido SACOL1867 según lo expuesto en cualquiera de las secuencias descritas en Fig. 25D (SEC ID Nº 152 a 164), un polipéptido SACOL1912 (SEC ID Nº 43), un polipéptido SACOL1944 (SEC ID Nº 190), un polipéptido SACOL2144 (SEC ID Nº 191), un polipéptido SACOL2365 (SEC ID Nº 192), un polipéptido SACOL2385 (SEC ID Nº 50) o un polipéptido SACOL2599 (SEC ID Nº 193), sobre la base de la nomenclatura genética del genoma COL (SACOL) de Staphylococcus aureus expuesto en la Secuencia de Referencia en el NCBI NC_002951.2; (b) un polipéptido codificado por un gen de un mismo operón que un gen que codifica al polipéptido de (a); (c) un polipéptido que comprende un fragmento inmunogénico de por lo menos 13 aminoácidos consecutivos de (a) o (b); (d) un polipéptido que comprende una secuencia de aminoácidos por lo menos 60% idéntica en su totalidad a la secuencia del polipéptido de cualquiera de (a) a (c); o (e) un polipéptido que comprende una variante inmunogénica que comprende por lo menos 13 aminoácidos consecutivos de cualquiera de (a) a (c); (2) el ligante es una secuencia de aminoácidos de por lo menos un aminoácido o está ausente; (3) X está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido; y (4) Z está ausente o es una secuencia de aminoácidos de por lo menos un aminoácido. Se proporcionan además composiciones y kits que comprenden la fusión y usos de estas fusiones, composiciones y kits.
ARP170102922A 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus AR109847A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
AR109847A1 true AR109847A1 (es) 2019-01-30

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102922A AR109847A1 (es) 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (es)
EP (1) EP3529260A4 (es)
JP (2) JP7181208B2 (es)
KR (1) KR20190082229A (es)
CN (1) CN109843910A (es)
AR (1) AR109847A1 (es)
AU (2) AU2017346974B2 (es)
BR (1) BR112019007796A2 (es)
CA (1) CA3037070A1 (es)
CL (1) CL2019001048A1 (es)
CO (1) CO2019005169A2 (es)
CR (1) CR20190249A (es)
DO (1) DOP2019000102A (es)
IL (1) IL265869A (es)
MX (2) MX2019004539A (es)
MY (1) MY195369A (es)
NZ (1) NZ751880A (es)
PE (1) PE20191320A1 (es)
PH (1) PH12019500843A1 (es)
RU (2) RU2022100889A (es)
SG (2) SG11201901483QA (es)
TW (1) TW201819402A (es)
UY (1) UY37448A (es)
WO (1) WO2018072031A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220185852A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3669503D1 (de) 1985-01-07 1990-04-19 Syntex Inc Oberflaechenaktive n-(omega, omega-1-dialkoxy)- und n-(omega, omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituierte ammoniumverbindungen, deren herstellung und sie enthaltende pharmazeutische formulierungen.
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
CA2583121A1 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
WO2006059846A1 (en) 2004-12-01 2006-06-08 Lg Life Sciences, Ltd. Formulation of sec1 mutated protein and method for formulation of the same
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
NZ595231A (en) * 2009-03-23 2014-03-28 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
BRPI1013780B8 (pt) * 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
EP2547361B1 (en) 2010-03-17 2020-10-28 SOCPRA - Sciences et Génie, s.e.c. Bacterial vaccine components from staphylococcus aureus and uses thereof
NZ764564A (en) 2011-06-19 2022-10-28 Univ New York Methods of treating and preventing staphylococcus aureus infections and associated conditions

Also Published As

Publication number Publication date
CN109843910A (zh) 2019-06-04
EP3529260A1 (en) 2019-08-28
RU2019115303A (ru) 2020-11-23
JP2019531100A (ja) 2019-10-31
PH12019500843A1 (en) 2019-12-02
KR20190082229A (ko) 2019-07-09
CO2019005169A2 (es) 2019-08-09
SG10201912431XA (en) 2020-02-27
BR112019007796A2 (pt) 2019-09-03
NZ751880A (en) 2023-04-28
RU2022100889A (ru) 2022-04-06
CL2019001048A1 (es) 2019-08-30
SG11201901483QA (en) 2019-03-28
AU2022204585A1 (en) 2022-07-21
IL265869A (en) 2019-06-30
CA3037070A1 (en) 2018-04-26
PE20191320A1 (es) 2019-09-24
US20190216913A1 (en) 2019-07-18
UY37448A (es) 2018-03-23
JP7181208B2 (ja) 2022-11-30
RU2019115303A3 (es) 2021-03-02
AU2017346974A1 (en) 2019-03-14
MX2019004539A (es) 2019-06-12
EP3529260A4 (en) 2020-12-16
JP2023025066A (ja) 2023-02-21
US11324815B2 (en) 2022-05-10
WO2018072031A1 (en) 2018-04-26
MY195369A (en) 2023-01-16
CR20190249A (es) 2019-10-16
US20220288183A1 (en) 2022-09-15
MX2023001219A (es) 2023-03-03
TW201819402A (zh) 2018-06-01
AU2017346974B2 (en) 2022-03-31
RU2766354C2 (ru) 2022-03-15
DOP2019000102A (es) 2019-07-15

Similar Documents

Publication Publication Date Title
EA201991442A1 (ru) ТЕРМОСТАБИЛЬНЫЕ НУКЛЕАЗЫ Cas9
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CY1118331T1 (el) Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων
CO2017006495A2 (es) Bacteriófago esc-cop-1 de e. coli tipo f18 productora de toxina shiga para inhibir la proliferación de e. coli tipo f18 productora de toxina shiga
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR070058A1 (es) Enzima bacteriana asociada con la sintesis de ecuol
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
CO2018006947A2 (es) Novedoso bacteriófago pas-mup-1 de pasteurella multocida y su uso para inhibir la proliferación de pasteurella multocida
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
BR112022004453A2 (pt) Retroelemento bacteriano modificado com produção intensificada de dna
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
AR065282A1 (es) Composiciones y metodos que utilizan arn de transferencia de genes tipo cad para el control de nematodos
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CO2019005169A2 (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
MY187334A (en) Xylanase
AR102963A1 (es) Composiciones y métodos para controlar las plagas en plantas
AR100824A1 (es) Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae
AR056782A1 (es) Uso de polinucleotidos armadillo repeat (arm1) para lograr una resitencia contra agentes patogenos en plantas
WO2014151687A3 (en) Compositions and methods to treat aids